Foundation Medicine Inc (FMI)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Foundation Medicine Inc (FMI) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011701
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd is a healthcare products provider that offers cancer care solutions. The company offers molecular information and cancer research programs. It offers clinical products which include FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas and others. It also offers additional materials, services, and real-time data through its technology products. The company partners with biotech and pharmaceutical companies to develop targeted cancer therapies and active clinical trials. Foundation Medicine is headquartered in Cambridge, Massachusetts, the US.

Foundation Medicine Inc (FMI) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Foundation Medicine Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Foundation Medicine Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Cota Raises Funds through Venture Financing 12
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 17
Partnerships 18
Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Enters into Agreement with Mirati Therapeutics 20
IMS Health Enters into Agreement with Foundation Medicine 21
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 22
Foundation Medicine Extends Co-Development Agreement With Clovis Oncology 23
Foundation Medicine Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 24
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 25
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 26
Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 27
Foundation Medicine Extends Co-Development Agreement With Novartis 28
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 29
Foundation Medicine Enters Into An Agreement With Novartis 30
Foundation Medicine Expands Co-Development Agreement With Novartis 31
Equity Offering 32
Foundation Medicine Raises USD250 Million in Private Placement of Shares 32
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 33
Foundation Medicine Completes IPO Of Shares For US$122 Million 34
Foundation Medicine Inc – Key Competitors 35
Foundation Medicine Inc – Key Employees 36
Foundation Medicine Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Strategy And Business Planning 38
Jun 08, 2017: ASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization Study 38
Financial Announcements 39
Nov 01, 2017: Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights 39
Aug 01, 2017: Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights 40
May 09, 2017: Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights 42
Feb 22, 2017: Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook 44
Jan 09, 2017: Foundation Medicine Reports Preliminary 2016 Results 45
Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights 47
Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights 49
May 03, 2016: Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights 51
Feb 23, 2016: Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook 52
Corporate Communications 53
Oct 10, 2017: Foundation Medicine Appoints Tom Civik as Chief Commercial Officer 53
Jan 06, 2017: Foundation Medicine Announces Executive Leadership Transition 54
Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors 55
Legal and Regulatory 56
Nov 07, 2017: Caris Life Sciences Files Patent Infringement Suit against Foundation Medicine 56
Government and Public Interest 57
Aug 15, 2017: Cancer Treatment Centers Of America And Foundation Medicine Join Forces to Advance Precision Cancer Treatment 57
Product News 58
May 18, 2017: Foundation Medicine and Its Collaborators to Present New Data at ASCO 2017 Supporting the Integration of Comprehensive Genomic Profiling in Personalized Clinical Care in Oncology 58
Aug 22, 2016: Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products 60
May 17, 2016: Foundation Medicine Receives Patent Covering Fundamental Methods in Comprehensive Genomic Analysis in Cancer 61
03/23/2016: Foundation Medicine and Memorial Sloan Kettering Publish Validation Data for FoundationOne Heme in the Journal Blood 62
03/17/2016: Foundation Medicine Announces Presentations at the AACR Annual Meeting 2016 64
03/16/2016: Foundation Medicine Presents New Data at the 2016 USCAP Annual Meeting Underscoring Importance of Comprehensive Genomic Profiling in Cancer Care 66
Other Significant Developments 68
Feb 25, 2016: Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Foundation Medicine Inc, Medical Equipment, Key Facts, 2016 2
Foundation Medicine Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Foundation Medicine Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Deals By Market, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cota Raises Funds through Venture Financing 12
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 17
Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Enters into Agreement with Mirati Therapeutics 20
IMS Health Enters into Agreement with Foundation Medicine 21
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 22
Foundation Medicine Extends Co-Development Agreement With Clovis Oncology 23
Foundation Medicine Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 24
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 25
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 26
Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 27
Foundation Medicine Extends Co-Development Agreement With Novartis 28
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 29
Foundation Medicine Enters Into An Agreement With Novartis 30
Foundation Medicine Expands Co-Development Agreement With Novartis 31
Foundation Medicine Raises USD250 Million in Private Placement of Shares 32
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 33
Foundation Medicine Completes IPO Of Shares For US$122 Million 34
Foundation Medicine Inc, Key Competitors 35
Foundation Medicine Inc, Key Employees 36
Foundation Medicine Inc, Other Locations 37

★海外企業調査レポート[Foundation Medicine Inc (FMI)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SunPower Corporation (SPWR):企業概要、財務及び戦略的SWOT分析
    SunPower Corporation (SPWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Nodality, Inc.:(医療機器分野)企業M&A及び提携動向
    Summary Nodality, Inc. (Nodality) is a biotechnology company. The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients. It develops molecular diagnostics to improve clinic …
  • Sui Northern Gas Pipelines Ltd (SNGP):企業の財務・戦略的SWOT分析
    Sui Northern Gas Pipelines Ltd (SNGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Raiffeisen Group:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Raiffeisen Group" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly follows …
  • Sonae SGPS SA:企業の戦略・SWOT・財務分析
    SummarySonae SGPS SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings …
  • Gastar Exploration, Inc. (formerly Gastar Exploration, Ltd.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Gastar Exploration, Inc. (forme …
  • pSivida Corp (PSDV):企業のM&A・提携動向(医療機器分野)
    Summary pSivida Corp (pSivida) is a medical device company that provides miniaturized and sustained release drug delivery products. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, which is used for th …
  • Renren Inc.:企業のM&A・提携・投資分析
    Renren Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Renren Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Chelyabinsk Pipe-Rolling Plant OJSC:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Chelyabinsk Pipe-Rolling Plant …
  • Giralia Resources NL:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Giralia Resources NL Mergers an …
  • Centers for Disease Control and Prevention:(医療機器分野)企業M&A及び提携動向
    Summary Centers for Disease Control and Prevention (CDC) is a health protection agency. It focuses on protecting people from health, safety and security threats. The company provides health information to fights disease and support communities from expensive and dangerous health threats. It offers s …
  • Randstad Holding nv:企業の戦略・SWOT・財務分析
    SummaryRandstad Holding nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fin …
  • GP Strategies Corporation (GPX):企業の財務及び戦略的SWOT分析
    Summary GP Strategies Corporation (GP Strategies) is performance improvement firm that offers customized training, curriculum design and development, e-learning, system hosting, and training business process outsourcing and consulting services. The firm provides engineering and technical solutions f …
  • Ferrovial, S.A. (formerly Grupo Ferrovial S.A.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Ferrovial, S.A. (formerly Grupo …
  • Telecity Group plc (formerly TelecityRedbus):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Telecity Group plc (formerly Te …
  • Abzena Plc (ABZA):企業財務及び戦略的SWOT分析
    Summary Abzena Plc (Abzena), formerly Polytherics Group Limited is a life science company that offers complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company services and technolog …
  • Nippon Kayaku Co., Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Nippon Kayaku Co., Ltd. Mergers …
  • Qsc AG (QSC):企業の財務及び戦略的SWOT分析
    Summary Qsc AG (Qsc) is a communication company that provides integrated telecommunication and managed services. The company’s services include broadband network connections, managed services, software based telephone systems IP centrex, IP -VPN networks, and direct connections QSC voice network. It …
  • Collegium Pharmaceutical, Inc. (COLL):企業のM&A・提携動向(医療機器分野)
    Summary Collegium Pharmaceutical, Inc. (Collegium) is a specialty pharmaceutical company, which develops products for the treatment of chronic pain that incorporate its DETERx oral drug delivery technology. Collegium’s lead candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formula …
  • Bohae Brewery Co., Ltd.:企業概要・SWOT・財務分析
    Summary Canadean's "Bohae Brewery Co., Ltd. : Consumer Packaged Goods - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆